BACKGROUND: Recent policy initiatives in Baltimore City, MD significantly reduced access disparities between methadone and buprenorphine in the publicly funded treatment sector. OBJECTIVES: This study examines reasons for choosing buprenorphine over methadone among patients with access to both medications. METHOD: This study was embedded within a larger clinical trial conducted at two outpatient substance abuse treatment programs offering buprenorphine. Qualitative and quantitative data on treatment choice were collected for new patients starting buprenorphine treatment (n = 80). The sample consisted of predominantly urban African American (94%) heroin users who had prior experience with non-prescribed street buprenorphine (85%), and opioid agonist treatment (68%). Qualitative data were transcribed and coded for themes, while quantitative data were analyzed using descriptive and bivariate statistics. RESULTS: Participants typically conveyed their choice of buprenorphine treatment as a decision against methadone. Buprenorphine was perceived as a helpful medication while methadone was perceived as a harmful narcotic with multiple unwanted physical effects. Positive experiences with non-prescribed "street buprenorphine" were a central factor in participants' decisions to seek buprenorphine treatment. CONCLUSIONS: Differences in service structure between methadone and buprenorphine did not strongly influence treatment-seeking decisions in this sample. Personal experiences with medications and the street narrative surrounding them play an important role in treatment selection decisions. SCIENTIFIC SIGNIFICANCE: This study characterizes important decision factors that underlie patients' selection of buprenorphine over methadone treatment.
BACKGROUND: Recent policy initiatives in Baltimore City, MD significantly reduced access disparities between methadone and buprenorphine in the publicly funded treatment sector. OBJECTIVES: This study examines reasons for choosing buprenorphine over methadone among patients with access to both medications. METHOD: This study was embedded within a larger clinical trial conducted at two outpatient substance abuse treatment programs offering buprenorphine. Qualitative and quantitative data on treatment choice were collected for new patients starting buprenorphine treatment (n = 80). The sample consisted of predominantly urban African American (94%) heroin users who had prior experience with non-prescribed street buprenorphine (85%), and opioid agonist treatment (68%). Qualitative data were transcribed and coded for themes, while quantitative data were analyzed using descriptive and bivariate statistics. RESULTS:Participants typically conveyed their choice of buprenorphine treatment as a decision against methadone. Buprenorphine was perceived as a helpful medication while methadone was perceived as a harmful narcotic with multiple unwanted physical effects. Positive experiences with non-prescribed "street buprenorphine" were a central factor in participants' decisions to seek buprenorphine treatment. CONCLUSIONS: Differences in service structure between methadone and buprenorphine did not strongly influence treatment-seeking decisions in this sample. Personal experiences with medications and the street narrative surrounding them play an important role in treatment selection decisions. SCIENTIFIC SIGNIFICANCE: This study characterizes important decision factors that underlie patients' selection of buprenorphine over methadone treatment.
Authors: Chris-Ellyn Johanson; Cynthia L Arfken; Salvatore di Menza; Charles Roberts Schuster Journal: Drug Alcohol Depend Date: 2011-08-21 Impact factor: 4.492
Authors: Shannon Gwin Mitchell; Rika Morioka; Heather Schacht Reisinger; James A Peterson; Sharon M Kelly; Michael H Agar; Barry S Brown; Kevin E O'Grady; Robert P Schwartz Journal: J Psychoactive Drugs Date: 2011 Apr-Jun
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; James A Peterson; Heather S Reisinger; Shannon G Mitchell; Monique E Wilson; Michael H Agar; Barry S Brown Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz Journal: J Psychoactive Drugs Date: 2009-06
Authors: Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz Journal: Am J Addict Date: 2009 Sep-Oct
Authors: Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079
Authors: Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice Journal: J Subst Abuse Treat Date: 2019-01-26